Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pacific Biosciences of California's enterprise value is $849.8 Mil.
Pacific Biosciences of California's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-103.1 Mil. Therefore, Pacific Biosciences of California's EV-to-EBITDA for today is -8.24.
The historical rank and industry rank for Pacific Biosciences of California's EV-to-EBITDA or its related term are showing as below:
PACB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -131.91 Med: -7.71 Max: 283.78
Current: -8.24
During the past 13 years, the highest EV-to-EBITDA of Pacific Biosciences of California was 283.78. The lowest was -131.91. And the median was -7.71.
PACB's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.845
vs PACB: -8.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Pacific Biosciences of California (NAS:PACB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pacific Biosciences of California's PE Ratio (TTM) for today is calculated as:
Pacific Biosciences of California's share price for today is $1.36.
Pacific Biosciences of California's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California EV-to-EBITDA Chart
For the Medical Devices subindustry, Pacific Biosciences of California's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's EV-to-EBITDA falls into.
Pacific Biosciences of California's current Enterprise Value is $849.8 Mil.
Pacific Biosciences of California's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a EV-to-EBITDA of -8.24 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pacific Biosciences of California. According to the industry distribution chart, Pacific Biosciences of California ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is Pacific Biosciences of California's EV-to-EBITDA too high?
Pacific Biosciences of California's current EV-to-EBITDA is -8.24. Based on the distribution chart, Pacific Biosciences of California ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pacific Biosciences of California has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's EV-to-EBITDA compare to KIDS and MOBI?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #999999 out of 510 companies for EV-to-EBITDA. This places Pacific Biosciences of California in the lower half of its industry. The industry median EV-to-EBITDA is 13.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.85, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pacific Biosciences of California. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current EV-to-EBITDA is -8.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.62, compared to a current price of $1.36 — trading 16% below its estimated fair value. The current EV-to-EBITDA is -8.24. Pacific Biosciences of California's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current EV-to-EBITDA is -8.24 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.36 is trading 16% below its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Modestly Undervalued.
Key valuation signals for PACB:
EV-to-EBITDA: -8.24
GF Value™: $1.62 vs. price of $1.36 (16% below fair value)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for PACB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
